Obesity is a major health problem in the U.S. However, how adipose tissue disorders cause metabolic diseases is not well understood. Study of familial lipodystrophies which are characterized by partial (familial partial lipodystrophies; FPL) or almost complete lack of body fat (congenital generalized lipodystrophy, CGL) and metabolic complications may elucidate the mechanisms involved. Recently, FPL was reported to be due to defects in lamin A/C (LMNA) and peroxisome proliferator-activated receptor-g (PPARG) genes and CGL due to mutations in 1- acylglycerol-3-phosphate O-acyltransferase 2 (AGPA T2) or Seipin genes on chromosome 9q34 and 11q13, respectively. The main aim of this proposal is to identify additional gene(s) that cause CGL and FPL. Another aim is to define the role of AGPAT2 mutations in adipose tissue biology and development by conducting functional studies and by developing a knockout Agpat2 mouse model. To accomplish these aims, we have collected a number of well-characterized CGL pedigrees, which do not harbor substantial alterations in AGPAT2 and Seipin and FPL pedigrees without alterations in LMNA and PPARG. We will carefully characterize minor changes in the phenotype by studying body fat distribution by anthropometry and whole body magnetic resonance imaging and will ascertain severity of metabolic complications by measuring insulin sensitivity, plasma lipoproteins, free fatty acids, glycerol, leptin and other metabolic variables. Additional locus (loci) for CGL and FPL will be determined by genome-wide linkage analysis. Following chromosomal localization and fine mapping, candidate genes, already mapped or identified in these regions will be examined for mutations using direct sequencing. The identification of novel genes responsible for CGL and FPL and understanding of the role of AGPATs in adipocyte biology will lead to a better understanding of how common adipose tissue disorders such as obesity cause insulin resistance and other metabolic complications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK054387-05
Application #
6617231
Study Section
Metabolism Study Section (MET)
Program Officer
Mckeon, Catherine T
Project Start
1999-05-15
Project End
2007-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
5
Fiscal Year
2003
Total Cost
$503,194
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Agarwal, Anil K; Tunison, Katie; Dalal, Jasbir S et al. (2017) Metabolic, Reproductive, and Neurologic Abnormalities in Agpat1-Null Mice. Endocrinology 158:3954-3973
Agarwal, Anil K; Tunison, Katie; Dalal, Jasbir S et al. (2016) Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2-/-) or obese (ob/ob) mice. J Lipid Res 57:616-30
Sankella, Shireesha; Garg, Abhimanyu; Agarwal, Anil K (2016) Characterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells. PLoS One 11:e0162504
Cautivo, Kelly M; Lizama, Carlos O; Tapia, Pablo J et al. (2016) AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. Mol Metab 5:491-505
Garg, Abhimanyu; Kircher, Martin; Del Campo, Miguel et al. (2015) Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. Am J Med Genet A 167A:1796-806
Patni, Nivedita; Alves, Crésio; von Schnurbein, Julia et al. (2015) A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma. J Clin Endocrinol Metab 100:3603-6
Garg, Abhimanyu; Xing, Chao (2014) De novo heterozygous FBN1 mutations in the extreme C-terminal region cause progeroid fibrillinopathy. Am J Med Genet A 164A:1341-5
Agarwal, Anil K; Sankella, Shireesha (2014) Phosphatidic acid: a new therapeutic lead to suppress hepatic glucose production. Diabetes Manag (Lond) 4:323-326
Sankella, Shireesha; Garg, Abhimanyu; Horton, Jay D et al. (2014) Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic Agpat2-/- mice. J Biol Chem 289:4762-77
Cortés, Víctor A; Cautivo, Kelly M; Rong, Shunxing et al. (2014) Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors. J Lipid Res 55:276-88

Showing the most recent 10 out of 82 publications